Sun Pharmaceutical Industries Ltd (SUN.NS)
26 Dec 2014
|Market Cap (Mil.):||Rs1,680,025.00|
|Shares Outstanding (Mil.):||2,071.16|
(Adds Mizuho, Oriola-KD, Sharp, Vattenfall, TriMas Corp, Abris Capital)
(Removes erroneous reference to Canadian Solar in Sharp Corp item)
* Shares rise 6 pct, outpacing market (Adds details on results, shares, context)
- Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.
MUMBAI - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.
MUMBAI, Sept 4 - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.
MUMBAI, July 29 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by local rival Sun Pharmaceutical Industries Ltd, posted a net loss in the June quarter hit by a one-time provision.
MUMBAI, July 16 - Sun Pharmaceutical Industries Ltd, India's third-largest generic drugmaker by sales, said on Wednesday it had acquired U.S.-based Pharmalucence Inc, which has sterile injectable capacity and research capabilities.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Sun Pharmaceutical Industries Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: SMC Global Securities Limited
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.